The study shows DMF provides therapeutic benefits including reduced hepatic necrosis and inflammation, yet plasma hemoglobin and heme levels remained unchanged, indicating hemolysis was not decreased. This contradicts the expected mechanism where reducing oxidative stress should decrease hemolysis-driven pathology. Gap type: contradiction Source paper: Control of Oxidative Stress and Inflammation in Sickle Cell Disease with the Nrf2 Activator Dimethyl Fumarate. (2017, Antioxidants & redox signaling, PMID:26914345)
Landscape Summary: How does DMF improve sickle cell pathology without reducing hemolysis or plasma heme levels? is a 0.8 priority gap in oxidative-stress-biology. It has 0 linked hypotheses with average composite score 0.000. Status: open.
Colonna, Sevlever, et al. (TREM2 biology)
How does DMF improve sickle cell pathology without reducing hemolysis or plasma heme levels? — INVOKE-2 (completed)
No hypotheses linked to this gap yet.
No activity recorded yet.
No discussions yet. Be the first to comment.
Create sub-tasks to investigate specific aspects of this gap: